Results from a Cleveland Clinic Phase 1, first-in-human clinical trial showed that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 safely reduced LDL (“bad”) cholesterol and triglycerides in...
The Verdict
ClassificationLikely Human
ConfidenceMedium confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/abd162b3-c78d-42ff-9b76-b4d7612102ad)